Rigel Pharmaceuticals (RIGL) Corporate presentation summary

Strategic growth and business development

• Executed exclusive global license for VEPPANU, the first FDA-approved oral PROTAC for ER+/HER2-, ESR1m advanced or metastatic breast cancer, with commercial launch set for mid-August 2026.

• Transformation from one to four commercial products by 2030s, with expansion through in-licensing and M&A.

• Annual net product sales projected to grow at a 35% CAGR, reaching $232M–$260M by 2026, excluding VEPPANU.

• In-licensing strategy focuses on late-stage, differentiated assets in hematology and oncology, leveraging existing infrastructure for rapid accretion.

Commercial performance and product portfolio

• Q2 2026 net product sales reached $67M, up 14% year-over-year, with TAVALISSE, GAVRETO, and REZLIDHIA all showing double-digit growth.

• TAVALISSE is indicated for chronic immune thrombocytopenia, with significant market share and efficacy across multiple lines of therapy.

• REZLIDHIA targets relapsed/refractory AML with IDH1 mutation, showing a 35% CR+CRh rate and durable responses in Phase 2 trials.

• GAVRETO is approved for RET fusion-positive NSCLC and thyroid cancer, offering once-daily oral dosing and strong efficacy regardless of prior treatment.

• Global expansion includes launches and regulatory approvals for TAVALISSE and REZLIDHIA in multiple international markets.

VEPPANU (vepdegestrant) clinical and commercial highlights

• VEPPANU is the first FDA-approved PROTAC, offering a novel mechanism for ER degradation and potential to become a market leader in 2L+ ER+/HER2-, ESR1m metastatic breast cancer.

• VERITAC-2 Phase 3 trial showed VEPPANU improved median PFS by 2.9 months (5.0 vs 2.1) and doubled ORR and CBR compared to fulvestrant in ESR1m patients.

• Safety profile is manageable, with low rates of discontinuation and dose reductions; most common adverse events were mild to moderate.

• Commercial launch readiness includes immediate deployment of sales force, patient services, and omnichannel campaigns.